Preparation eliciting with immunomodulating activity

FIELD: medicine, phytotherapy, pharmacy.

SUBSTANCE: invention relates to preparations of vegetable origin. Invention proposes the preparation eliciting immunomodulating effect and comprising aqueous-alcoholic extracts of the following plants, mas. p. p.: glabrous licorice roots, 5.0-15.0; fenestrate Saint-John's-wort herb 4.0-16.0; dandelion roots, 4.0-16.0; sandy immortelle flowers, 3.5-14.0; senna leaves, 3.5-14.0; thyme herb, 1.0-4.0; snowdon rose (rosewort) rhizomes and roots, 0.05-0.2. Also, invention proposes the preparation comprising condensed or an aqueous-alcoholic extract of above said plants and a filling agent. The preparation can be made as tablet or capsule. The preparation normalizes the blood free radicals content and provides elevating level of T-suppressors with the simultaneous reducing amount of T-helpers in blood of patients in treatment of acute and chronic inflammatory diseases of breathing organs.

EFFECT: valuable medicinal properties of preparation.

2 cl, 3 tbl, 1 ex

 

The present invention relates to medicine, in particular to drugs derived from medicinal plants and possessing immunomodulatory activity.

Known biostimulator "Immuvit" (A.S. SU 1816217), which is a dried extract of freshly harvested medicinal raw material containing (in parts): 2-4 parts aloe, 1,0-1,5 - St. John's wort, 0,5-1,5 - kidney pine, 1,5-4,0 - Swede, 2,0-5,5 - nettle leaves, 0.5 to 1.5 - blueberries, 0,5-1,5 - birch leaves, which is used as a food additive, which improves health and reduces the frequency of colds.

Known means (A.S. SU 858833)improving the health of the body and represents the ethyl acetate extract of roots and rhizomes of Burnet, precipitated with chloroform and dried in vacuum. The extract has antihypoxic effect and stimulates heart activity.

Known means (A.S. SU 1797894), which is a dried 40% ethanol extract of plant collecting, containing, wt.%: the leaves of the aloe tree 29-31, grass knotweed 9-10, grass clover plow 9-11, leaves three leaf watch 9-11, leaves, seaweed 9-11, oak bark 25-35. The extract improves faguoqitirute the ability of white blood cells.

It is also known agent (patent RU 2200023 published 10.03.2003,), which has an immunomodulatory effect and represents a liquid water-spirtuality of the herb Hypericum perforatum, dandelion root, immortelle sandy, Senna leaf, thyme herb, rhizome and roots of Rhodiola rosea, taken in the following ratio, including: 7,0-14,0:7,0-14,0:6,0-12,0:6,0-12,0:2,0-5,0:0,05-0,3, which is intended for treating immunodeficiencies caused cancer pathology and chemotherapeutic treatment of cancer patients.

The main task to be solved by the invention, consists in expanding the range of medicinal products intended for the correction of immunological activity of the organism, an alternative for cases of individual intolerance of the individual ingredients.

Another task is to improve the effectiveness of the drug in the treatment of acute and chronic inflammatory diseases, mainly of the respiratory system, by increasing the phagocytic activity of neutrophils and normalization of cellular and humoral immunity.

Another task is to normalize the content of free radicals in the blood of the patient.

The task is solved by the fact that the proposed drug with immunomodulatory effects, including aqueous-alcoholic extract of medicinal plants, which, according to the invention, represents an extract of licorice root, herb St. John's wort, dandelion root, flowers be the suicide sandy, Senna leaf, thyme herb, rhizome and roots of Rhodiola rosea, taken in the following ratio, including: 5,0-15,0:4,0-16,0:4,0-16,0:3,5-14,0:3,5-14,0:1,0-4,0:0,05-0,2.

The product mainly contains extract of licorice root, herb St. John's wort, dandelion root, immortelle sandy, Senna leaf, thyme herb, rhizome and roots of Rhodiola rosea, taken in the following ratio, including: 8,0-12,0:6,0-10,0:6,0-10,0:5,0-9,0:5,0-9,0:1,0-3,0:0,07-0,15. The specified product contains thiamine (vitamin b1at least 0,0001 mg/ml Riboflavin (vitamin b2at least 0,00035 mg/ml, Pantothenic acid (vitamin b3at least 0.035 mg/ml pyridoxine (vitamin b6at least 0,0001 mg/ml folic acid (vitamin b9at least 0.1 mg/ml ascorbic acid (vitamin C) at least 0,033 mg/ml, tannins at least 0.5 mg/ml inulin at least 2 mg/ml, the amount of flavonoids rutin at least 0.5 mg/ml, including γ-tocopherol, at least 0.005 mg/ml, lycopene at least 0.002 mg/ml, β-cryptoxanthin at least 0.01 mg/ml, α-carotene at least 0.05 mg/ml, β-carotene at least 0.33 mg/ml of the Drug can be prepared in the form of an elixir or tablets, or capsules.

The preparation may contain the specified water-alcoholic extract of medicinal plants is in condensed (concentrated or dry form.

The preparation can further comprise a filler in the following ratio of components, wt.%:

the specified dry hydro-alcoholic extract of medicinal plants is 1.0-10.0

filler 90-99%

As the filler, the preparation may contain magnesium oxide, or starch, or a mixture.

The drug is made in the form of tablets or capsules and contains as filler magnesium oxide and starch in the following ratio of components, wt.%:

dried specified aqueous-alcoholic extract of medicinal plants is 1.0-10.0

magnesium oxide 20-45,0

starch else

As extractant, the drug contains a mixture of 95% ethyl rectified spirit and water in the ratio of 1-2:1-2.

The product is obtained by processing the raw material in a mixture of ethanol and water in the ratio of raw material:extractant 1-2:30-60.

The invention consists in the fact that picked up the composition and ratio of plant components, the extractant and the conditions for the preparation containing tannins at least 0.5 mg/ml inulin at least 2 mg/ml, the amount of flavonoids rutin at least 0.5 mg/ml, including γ-tocopherol, at least 0.005 mg/ml, lycopene at least 0.002 mg/ml, β-cryptoxanthin at least 0.01 mg/ml, α-carotene at least 0.05 mg/ml, β-carotene at least 0.33 mg/is l, as well as thiamine (vitamin B1at least 0,0001 mg/ml Riboflavin (vitamin b2at least 0,00035 mg/ml, Pantothenic acid (vitamin b3at least 0.035 mg/ml pyridoxine (vitamin b6at least 0,0001 mg/ml folic acid (vitamin b9at least 0.1 mg/ml ascorbic acid (vitamin C) at least 0,033 mg/ml

The technical result consists in the fact that we offer the drug provides an increase in the content of T-suppressors with a simultaneous decrease in the number of T-helper cells in the blood of patients in the treatment of acute and chronic inflammatory diseases of the respiratory system that allows you to normalize immuno-regulatory index (IRI) people.

Clinical trials of the drug showed that in the treatment of acute and chronic inflammatory diseases of the respiratory system, it provides an improved function of the immune system, allowing it to be used for protection and prevention of nonspecific somatic diseases.

For the manufacture of the drug take-known medicinal plants:

The licorice - Glycyrrhiza glabra L. root which contains sugars, organic acids and their derivatives, tannins, flavonoids (liquiritin and its derivatives, licorise, separated, soraluze, URALSIB, formononetin (biochanin), glabra and its derivatives, 4-0-methylglabridin And 3-methoxypyridine, phaseolinae, hospilality And, hospilality, ononin, licochalcone a and b, 4-hydroxychalcone, quercetin, kaempferol, apigenin, heteroside), saponins, higher aliphatic hydrocarbons and alcohols (hydrolysate), higher fatty acids (GFH St, s).

Drugs licorice root contribute to the healing of experimental gastric ulcers, have anti-allergic properties, antianaphylactic effect, regulate water-salt metabolism.

St. John's wort - Hypericum perforatum, herb contains tannins, derivatives pyrocatechin, essential oil, flavonoids (hyperoside, rutin, quercetin, isoquercetin, quercitrin), azulene, dyes: hypericin, pseudohypericin, hypercoagulation, pseudohyperaldosteronism, frangulaemodin, carotene, arrowy alcohol, choline, vitamins C, PP, anthocyanins, saponins, resinous substances (GFH article 52, s).

The active substance of Hypericum have astringent, antibacterial, anti-inflammatory, biostimulation and marked choleretic action.

Flowers of immortelle sandy - Helichrysum arenarium (L.) Moench., which contain flavonoids, tannins (tannin), coumarins, saponins, resins, beta-phytosterol and others (GFH 9, s).

Drugs immortelle accelerate the clotting of blood, have the same cehennem and deworming effect.

The herb thyme (creeping thyme) - Nhymus serpyllium L., containing volatile oil, tannic and resinous substances, saponins and flavonoids (GFH article 60, s).

The preparations of the herb thyme have antiseptic and disinfectant action.

Dandelion root (dandelion) - Ttaraxaciim officinale contain flavonoids, inulin, bitter glycoside, taraxacin, organic acids, sugars, fatty oil, triterpene alcohols (GFH article 69, s).

Preparations of dandelion root have krovoochistitelnoe, diuretic, choleretic action. They are used for constipation, diabetes, renal colic and gout.

Senna leaf platanoides - Cassia acutifolia, containing flavonoids, including emodin, and anthraglycosides, including chrysophanol acid (GFH 23, s). Senna preparations take as a mild laxative to cleanse the body.

Rhizomes and roots of Rhodiola rosea - Rhodilae roseae L., contain essential oils, tannins, vitamins C and PP, flavones, organic acids, including oxalic, malic, citric, Gallic, and others, as well as the glycoside - salidroside (GFH article 75, s). Preparations of Rhodiola rosea is used to improve the physical and mental health, have a stimulating effect on the Central nervous system, contributing to the disappearance of irritability.

Sleep is t ethyl alcohol - GOST R 51652-2000.

Drinking water GOST 2874-82.

Magnesium oxide - GFH St.

Starch - GOST 7699-78.

Gelatine capsule - GFH, issue 2, s.

The invention is illustrated by the following examples of specific performance:

EXAMPLE 1.

To obtain the proposed drug was taken (g) 8.0 dandelion root, 8,0 herb Hypericum perforatum, 7,0 grass immortelle sandy, 7,0 Senna leaf, 2,0 thyme herb, 0.1 rhizomes and roots of Rhodiola rosea, 10,0 roots of licorice, 474,0 alcohol, ethyl alcohol, purified water to 1000 ml.

All components were mixed, kept at a temperature of 50°within 24 hours, then at room temperature for 24 hours. The extract obtained was poured, pressed and filtered.

The content of antioxidants in the extract was determined by high performance liquid chromatography.

The resulting extract contains tannins 0,57 mg/ml inulin of 2.3 mg/ml thiamine 0,00012 mg/ml Riboflavin 0,00037 mg/ml Pantothenic acid 0.037 mg/ml pyridoxine 0,0001 mg/ml folic acid is 0.12 mg/ml, ascorbic acid, 0.035 mg/ml, the amount of flavonoids rutin 0.6 mg/ml, including γ-tocopherol 0.006 mg/ml, lycopene 0.003 mg/ml, β-cryptoxanthin 0.012 mg/ml, α-carotene 0,056 mg/ml, β-carotene 0.35 mg/ml

To prepare the drug in the form of capsules took 300 ml water-SP is stowage extract and uniformly under stirring watered them with the mixture, consisting of 10 g of magnesium oxide and 19 g of starch. The resulting mass is put on metal pallets, dried at a temperature of 45°to a moisture content of 1%, and capsule machine was filled in gelatin capsules at a rate of 0.3 g mass on the capsule.

Test preparation was carried out on the basis of the Medical unit №4, Izhevsk.

The drug was administered to patients daily depending on the condition of the body within 20 days 2 capsules 2-3 times a day during meals.

The study included 27 patients with frequent manifestations of SARS, seasonal polynosis and patients with chronic pneumonia (10 patients - control group).

Of the 17 patients treated with the claimed preparation in the dose of 2 capsules 2 times a day for 20 days (experimental group), 7 patients suffered from chronic pneumonia, 3 patients with seasonal polynosis in the acute stage, 7 patients with acute respiratory viral infection (ARVI).

All patients in the experimental and control groups was carried out comprehensive conventional therapy with the use of nonsteroidal anti-inflammatory drugs, antibiotics, sulfonamides, and antihistamines.

Assessment of immune status was performed twice: before treatment and after the 20-day course of treatment.

Phagocytic activity of neutrophils was determined using the latex test with the accepted standard values of 55-70%.

Circulating immune complexes (CIC) was determined by the classical method of precipitation with polyethylene glycol 6000 with normative values 0-5%

Cellular immunity was assessed by the content of T-lymphocytes, T-helpers, T-suppressors and immune-regulatory index (IRI), presented as the ratio of T helper to T-suppressor. Increasing the value of IRI shows a weak suppressor activity, which can lead to autoallergic body. The reduction in IRI below normative values indicates a failure of the implementation of immunity and refers to immunodeficiency States, explaining the frequent incidence especially ARI. Components of cellular immunity was determined using techniques immunomagnetic separation (alternative method of flow cytometry).

The activity of T-lymphocytes was determined by means of a thermal reaction in a thermostat at a temperature of 37°C.

The titer of complement was determined by its hemolytic activity, standardized for 50% hemolysis.

Humoral immunity was assessed by the concentration of immunoglobulins a, M, G, using the method of Mancini radial immunodiffusion.

Statistical processing of the obtained results was performed according to student using a differential method of assessment data.

In table 1 Pref is found normative values of the studied immunological parameters.

Table 1
IndexNormative values
T-lymphocytes56-71%
T-helpers33-41%
T-suppressor10-15%
IRI2,0-3,0%
The activity of T-lymphocytesup to 30%
Immunoglobulin a0,96-2.5 g/l
Immunoglobulin M0,79-2.0 g/l
Immunoglobulin G8,84-12.0 g/l
The titer of complement20-40%
Phagocytosis55-70%
CEC0-5%

The study found that the admission of the proposed drug enhances the phagocytic activity of neutrophils. So, in 9 patients before treatment phagocytic activity of neutrophils were below normative values (less than 55%), on average, 45,2±3.5 percent. In 8 of them (88,9%) phagocytic activity of neutrophils was significantly increased to 60.3+3,5% (P<0.01), and on average 15.1±3.8 per cent. Moreover, the increase in phagocytic activity was accompanied by a significant decrease in the number of circulating immune complexes with 2,3±0.4-0.7±0,3% (P<0,01) in all patients.

The number of circulating IMM is the R complexes was significantly decreased in the vast number of patients (87,5%), taking the drug with 2.1±0.3 to 0.6±0,2% (P<0,01). That allows you to indicate more favorable for various diseases associated with impaired immunity.

It is established that the change of values of CEC and phagocytic activity in the control group is statistically unreliable. Prior to the admission of the proposed drug in 7 patients of the experimental group, often suffering from cancer, immune-regulatory index (IRI) was below their limit values (2.0 to 3.0%) and amounted to 1.5±0,1%, mainly due to the enhancement of suppressor activity of lymphocytes. In the control group IRI was below the normative values in 6 patients. Dynamics of indicators of immune status in patients with low value of IRI are shown in table 2.

Table 2
IndexExperimental group (n=7)Control group (n=6)
 Before the treatmentAfter the treatmentBefore the treatmentAfter the treatment
T-lymphocytes, %60,7±4,549,3± and 4.957,6±3,8to 49.9±5,1
T-helper %36,0±3,431,7±4,338,4 4,336,5±4,3
T-suppressors, %24,7±1,815,3±1,7**32,5±2,625,4±3,2
IRI, %1,5±0,12,1±0,3**1,4±0,11,8±0,2
The activity of T-lymphocytes27,3±1,920,4±4,528,2±0,726,5±3,4
%1,6±0,21,9±0,21,6±0,31,7±0,2
Immunoglobulin A, g/l1,4±0,21,8±0,51,5±0,21,7±0,5
Immunoglobulin M, g/l15,4±1,71±61,816,3±1,717,1±1,4
Immunoglobulin G, g/l33,0±1,933,8±3,225,4±2,438,5±3,3
The titer of complement55,6±6,858,0±4,546,8±8,258,0±5,0
Phagocytosis, %2,5±0,20,6±0,2**2,6±0,12,2±0,2
The CEC unit    
Note. Two Zvezdochka the mi (**) indicate significant change with a probability of error p< 0,01.

All patients with low IRI, under review was marked by a high level of T-suppressors. This state of cellular immunity testified weak readiness of the immune system to viral aggression that explained the frequent incidence observed in patients with SARS.

In the experimental group of patients, who proposed the preparation, marked decrease in suppressor activity of cellular immunity to 15.3±1,7% without increasing the content of T-helper cells (71,4%). While Iran increased significantly to 2.1±0,3% (P<0,01). The number of circulating immune complexes was significantly decreased (P<0,01) in all patients of this group, probably due to the increased activity

phagocytosis the overwhelming number of patients (71,4%) and increase of the titer of complement in 71,4% of patients.

In 10 patients with pneumonia and polynosis IRI was above their limit values (4,0+0,3%), mainly due to the increase in the number of T-helper cells (80.0% of patients).

The dynamics of the immune status in patients with high IRI (n=10) before and after drug administration of its 20-day course presented in Table 3.

Table 3
IndexBefore the treatmentAfter the treatment
T-l is mocity, %55,9±2,656,8±3,1
T-helper %44,6±2,138,3±2,4
T-suppressors, %11,3±0,918,5±1,6**
IRI, %4,0±0,32,3±0,3**
The activity of T-lymphocytes, %27,8±2,025,3±2,2
Immunoglobulin A, g/l2,4±0,22,2±0,2
Immunoglobulin M, g/l2,7±0,52,6±0,5
Immunoglobulin G, g/l13,1±0,614,8±0,8
The titer of complement32,7±2,629,0±2,6
Phagocytosis, %63,1±4,563,1±3,0
The CEC unit1,3±0,30,8±0,4
Note. Two asterisks (**) indicate significant change with a probability of error p<0,01.

The state of the immune system with high IRI indicates the imbalance in the immune system in the direction of increasing antibody production and subsequent autoallergic on the body's own cells.

As a result of application of the drug significantly increased the content of T-suppressors in 87.5% of patients to 18.5±1,% (P< 0,01) with concurrent moderate decrease in the number of T-helper cells in 75.0% of patients. This reduction in the number of T-helper cells below the permissible values not observed in any patient. Such dynamics of T-lymphocytes helped significantly reduce IRI all patients to 2.3±0,3% (P<0,01).

The state of humoral immunity was assessed by indicators such as Ig A, M, G, titer complement.

The immunoglobulins of the group And responsible for nonspecific immunity, exceeded the maximum allowable value only in one patient. At the end of a course of treatment with the use of the proposed drug concentration of immunoglobulin a is normalized. In both groups there was a trend toward normalization of antibody titers.

Immunoglobulins group M, which characterizes the exacerbation of the inflammatory process, exceeded the normative values in 5 patients. As a result of application of the drug decrease in this indicator occurred in 4 patients (80,0%)who received the full 30-day course of treatment.

Positive dynamics of indicators of cellular and humoral immunity was accompanied by a number of positive clinical symptoms. Dynamics of disappearance or reduction of clinical symptoms, such as inflammation, cough, pain, weakness, feeling of lack of air was faster in the experimental group is E.

When use of the drug in the treatment of these diseases was not observed in any adverse or allergic reactions. All patients noted for its good tolerability.

Clinical research on the use of the proposed drug has shown that it has a positive significant influence on the dynamics of two different parts of cellular immunity: the first link is measured by the level of phagocytic activity of neutrophils and the second measured level of blood T-lymphocytes.

In addition to these indicators were conducted blood tests with apparatus FRAS3 - photometer to determine the concentration of free radicals in whole blood (Free Radical Analytical System - FRAS), which is the concentration of free radicals) is determined in units “Carr”. One Carr corresponds to the concentration of hydrogen peroxide 0.08 mg%. The normal concentration of free radicals in the blood corresponds to a value not exceeding 250 Carr, borderline - 250-300 Carr, the value of more than 300 Carr characterizes strong, and more than 400 Carr is a very strong oxidative stress.

It was found that the content of free radicals in whole blood of patients who had an initial concentration of free radicals 350-400 Carr, declined to 250 Carr th the 2-week course of treatment with the proposed medication in the dose of 2 capsules 2 times a day.

Thus, this study allows to conclude that the drug can be used to improve the function of the immune system by increasing the phagocytic activity of neutrophils and normalization of cellular and humoral immunity, as well as to normalize the content of free radicals in the blood.

1. The drug, which has an immunomodulatory action containing aqueous-alcoholic extract of medicinal plants, characterized in that it is a root extract of licorice, herbs St. John's wort herb, dandelion root, immortelle sandy, Senna leaf, thyme herb, rhizome and roots of Rhodiola rosea, taken in the following ratio, including: 5,0-15,0:4,0-16,0:4,0-16,0:3,5-14,0:3,5-14,0:1,0-4,0:0,05-0,2.

2. The preparation according to claim 1, characterized in that it contains an extract of licorice root, herb St. John's wort, dandelion root, immortelle sandy, Senna leaf, thyme herb, rhizome and roots of Rhodiola rosea, taken mainly in the following ratio, including: 8,0-12,0:6,0-10,0:6,0-10,0:5,0-9,0:5,0-9,0:1,0-3,0:0,07-0,15.

3. The preparation according to claims 1 and 2, characterized in that the water-alcohol extract of medicinal plants contains thiamine (vitamin B1at least 0,0001 mg/ml Riboflavin (vitamin b2at least 0,0003 5 mg/ml, Pantothenic acid (VI is Amin 3at least 0.035 mg/ml pyridoxine (vitamin B6at least 0,mg/ml folic acid (vitamin b9at least 0.1 mg/ml ascorbic acid (vitamin C) at least 0,033 mg/ml, tannins at least 0.5 mg/ml inulin at least 2 mg/ml, the amount of flavonoids rutin at least 0.5 mg/ml, including γ-tocopherol, at least 0.005 mg/ml, lycopene at least 0.002 mg/ml, β-cryptoxanthin at least 0.01 mg/ml, α-carotene at least 0.05 mg/ml, β-carotene at least 0.33 mg/ml

4. The preparation according to claim 1, characterized in that it contains the specified aqueous-alcoholic extract in condensed or dry.

5. The drug, which has an immunomodulatory effect, characterized in that it contains a condensed or dry hydroalcoholic extract of medicinal plants and a filler, in the following ratio, wt.%: condensed or dry hydroalcoholic extract of medicinal plants is 1.0-10.0; filler 90,0-99,0.

6. The preparation according to claim 5, characterized in that the filler it contains magnesium oxide, or starch, or a mixture.

7. The preparation according to claim 5, characterized in that it is made in the form of tablets or capsules.



 

Same patents:

FIELD: medicine, obstetrics, gynecology.

SUBSTANCE: at the background of therapy conducted one should introduce derinate immunomodulator into the body of pregnant woman additionally nasally per 1-2 drops of 0.25%-solution into each nasal canal 5-8 times daily for 3-5 d and - parenterally per 5.0 ml of 1.5%-solution once daily for 3-8 d along with preparation that improves microcirculation and along with antioxidant at a certain sequence, moreover, derinate should be introduced 30-40 min after application of microcirculation-improving preparation, and antioxidant - 20-30 min after derinate's introduction. The present innovation favors decreased edemas, decreased body weight, stabilization of Macluer-Aldrich test that in its turn enables to avoid perinatal losses, decrease the risk for the development of fetoplacental insufficiency and intrauterine fetal infection.

EFFECT: higher efficiency of therapy.

1 ex, 2 tbl

The invention relates to biopharmacology and comes to obtain the aimed at restoring metabolic processes and correction functions of the immune system

Immunomodulator // 2240794
The invention relates to new biologically active substances from the class alkenylboronic acids and can be used in medicine and biology as the basis for making medicines

Currently, in the treatment of infectious-inflammatory, autoimmune and oncological diseases in clinical medicine is widely used medicines, which have immunomodulatory properties (I. B. Mikhailov

The invention relates to the pharmaceutical industry and relates to the connection of a number of oxyindole, namely ethyl ester of 6-bromo-4-dimethylaminomethyl-1-methyl-5-hydroxy-2-phenylthio-methylindolin-3-carboxylic acid hydrochloride, which is an active substance of the drug Arbidol, and the drug based on it in the form of gelatin capsules

The invention relates to new biologically active compounds, namely diglyceride glycyrrhizic acid methyl ester L-valine of formula (I), stimulating primary immune response

The invention relates to medicine

The invention relates to N-substituted indole-3-glycinamide General formula I, possess Antiasthmatic, antiallergic and immunosuppressive/immunomodulatory action

where R is hydrogen, (C1-C6)alkyl, and the alkyl group optionally contains one phenyl substituent, which, in turn, optionally contains at least one Deputy, selected from the group comprising halogen, methoxy, ethoxy, (C1-C6)alkyl; R1means phenyl cycle containing at least one Deputy, selected from the group comprising (C1-C6)alkoxy, hydroxy, nitro, (C1-C6)alkoxycarbonyl one or fluorine, or R1represents the balance of the pyridine of the formula II

where the carbon atoms 2, 3 and 4 of the remaining pyridine optionally have the same or different substituents R5and R6and R5and R6denote (C1-C6)alkyl or halogen, or R1presents arylamination-2-methylprop-1-ilen group, or R and R1together with the nitrogen atom to which IGN="ABSMIDDLE">

where R7denotes phenyl or pyridinyl; R2means (C1-C6)alkyl, which optionally contains a phenyl residue, which, in turn, optionally substituted with halogen, methoxy group or ethoxypropane, or related to R2(C1-C6)alkyl group optionally substituted 2-, 3 - or 4-pyridinium residue; R3and R4are the same or different substituents and represent hydrogen, hydroxy, (C1-C6)alkoxy, (C1-C3)alkoxycarbonyl or (C1-C3)alkoxycarbonyl(C1-C3)alkyl, or R3is cyclopentanecarbonitrile; Z denotes Oh, and alkyl, alkoxy or alkylamino mean as an unbranched group, such as methyl, ethyl, n-propyl, n-butyl, n-hexyl and branched alkyl groups such as isopropyl or tert-butylene group; halogen means fluorine, chlorine, bromine or iodine and alkoxygroup means methoxy, propoxy, butoxy, isopropoxy, isobutoxy or phenoxypropan, and their pharmaceutically acceptable salts with acids

The invention relates to medicine, pulmonology and thoracic surgery and can be used for postoperative management of patients about common fibro-cavernous pulmonary tuberculosis

The invention relates to the field of medicine and for the creation of means of plant origin

The invention relates to biochemical pharmacology and can be used in clinical medicine as an anti-inflammatory, wound healing, hemostatic, anti-cancer, deworming and cardiac tonic

FIELD: medicine, virology, pharmaceutical industry, pharmacy.

SUBSTANCE: invention proposes the preparation used for treatment of viral hepatitis C that comprises birch bark extract with the content of betulin above 70% and a pharmaceutically acceptable carrier. The preparation is administrated to patient by oral route. The preparation promotes to the effective treatment of viral hepatitis C. Invention can be used in treatment of viral hepatitis C.

EFFECT: valuable medicinal properties of agent.

4 cl, 2 tbl

FIELD: medicine, pharmaceutical industry.

SUBSTANCE: invention relates to agents used for treatment of chronic hepatitis. The hepatoprotective agent representing extract prepared from biomass of Maackia amurensis Rupr. et Maxim and obtained by the callus culture method comprises polyphenolic complex consisting of daidzein, retusin, genistein, formononetin, maackianin and medicarpin. The hepatoprotective agent promotes to effective treatment of chronic hepatitis.

EFFECT: valuable medicinal properties of agent.

2 tbl

FIELD: medicine.

SUBSTANCE: method involves using air-dried vegetable raw. Hollow horse-mint (Monarda) raw treated by steam is extracted with vegetable oil in the ratio raw : extract = 1:10 at heating for 5 h on water bath at temperature 60-70oC followed by filtration. Method provides the possibility for year-round manufacturing the hollow horse-mint (Monarda) oily extract eliciting with the high antibacterial and expressed anti-fungal activity.

EFFECT: improved preparing method.

1 tbl, 1 ex

FIELD: pharmaceutical industry and technology, pharmacy.

SUBSTANCE: invention relates to a method for preparing extract based on walnuts at milkwax stage of ripeness. Method for preparing extract based on walnuts involves grinding walnuts at milkwax stage of ripeness taken with pericarps, drying to air-dry state, mixing with wild rose fruits ground and dried to air-dry state and taken in the definite ratio of components followed by treatment with aviation kerosene and stirring at room temperature. Method provides preparing extract with the higher content of biologically valuable substances and to increase the assortment of vegetable supplements.

EFFECT: improved preparing method.

2 tbl

FIELD: organic chemistry, natural compounds, medicine, oncology.

SUBSTANCE: invention represents new saponin mixtures used for inhibition of initiation and activation of mammalian epithelial cell in pre-malignant or malignant state, for stimulation of apoptosis of mammalian malignant cell, prophylaxis of anomalous proliferation of mammalian epithelial cell, for treatment of inflammatory and regulation of angiogenesis in mammal. These mixtures are isolated form plants of species Acacia victoriae. Also, invention relates to methods for their applying. These compounds can comprise triterpene component, such as acacic or oleanolic acid to which oligosaccharides and monoterpenoid components are joined. Mixtures and compounds elicit properties associated with regulation of apoptosis and cytotoxicity of cells and strong anti-tumor effect with respect to different tumor cells.

EFFECT: valuable medicinal properties of compositions.

43 cl, 53 tbl, 50 dwg, 44 ex

FIELD: beauty products manufacturing.

SUBSTANCE: the present innovation deals with manufacturing cosmetic composition that contains solubilized cumic alcohol of a certain formula, glucose, ascorbic acid or compound which is split in skin up to glucose or ascorbic acid and a cosmetically acceptable carrier. Components should be taken at a certain quantitative ratio. The suggested composition improves expression of transglutaminase-1 and ceramides in skin cells and enhances absorption of glucose and ascorbic acid by cells.

EFFECT: higher efficiency.

1 cl, 5 ex, 12 tbl

FIELD: organic chemistry, chemical technology, agriculture.

SUBSTANCE: invention relates to a method for preparing the preparation comprising triterpenic acid water-soluble salts and additionally added protein-containing product and vegetable raw, the source of triterpenic acids taken in the following ratio of components, wt.-%: protein-containing product, 10-17; triterpenic acid sodium salts, 4-5, and vegetable raw, the balance. Method involves mixing triterpenic acid-containing vegetable raw with the protein-containing product taken in the ratio = (9-11):(1-2), mechanical-chemical treatment of this mixture in activator device, mixing of prepared semi-finished product with sodium carbonate or sodium hydrocarbonate taken in the ratio = (92-97):(3.5-8.3) and repeated treatment in the activator device. Method involves applying flow-type ball vibration-centrifugal or ellipse-centrifugal mills as the activator device that provide the acceleration of milling bodies up to 170-250 m/c2 and time for treatment for 1.5-3 min. Invention provides simplifying the process and the complex processing waste in lumber industry.

EFFECT: improved preparing method.

6 cl, 1 tbl, 6 ex

FIELD: medicine, hematology.

SUBSTANCE: invention relates to applying elm-leaf dropwort (Filipendula) above-ground part 40% alcoholic tincture as an agent stimulating erythroidal and granulocytic hemopoiesis stems in cytostatic myelorepressions. Agent promotes to effective stimulation of erythroidal and granulocytic hemopoiesis stems in cytostatic myelodepression. Invention is used for correction of disorders arising in blood system in administration of cytostatic preparations.

EFFECT: valuable medicinal properties of agent.

3 tbl

FIELD: medicine, cardiology, phytotherapy, pharmacy.

SUBSTANCE: invention relates to the field in development of an agent of vegetable origin used for improvement of the functional state and prophylaxis of organic alterations in cardiovascular system, in particular, atherosclerosis. The biologically active supplement used for prophylaxis of cardiovascular diseases, in particular, atherosclerosis comprises clover dry extract, haw-thorn flowers powder, ascorbic and nicotinic acids, and accessory substances taken in the definite ratio. The biologically active supplement is made in the form of tablet or capsule. No adverse responses observed in intake of the supplement. The blood cholesterol level was reduced to the normal value in 68% of patients and reducing morbidity with acute respiratory-viral infections has been noticed. In patients with ischemic heart disease with cholesterolemia the improvement of the state is noted on the background of conventional therapy: the moderate reducing the arterial pressure value in its elevation, improved in the state of health, enhanced working capacity, reduced retrosternal pains, ear noise, vertigo, headache.

EFFECT: valuable medicinal properties of supplement.

1 ex

The hemostatic tool // 2242987
The invention relates to the field of medical pharmacology, namely organic geostatical used to stop the capillary and mixed hemorrhage in traumatic lesions of the skin and muscle tissue in surgical practice

FIELD: medicine, cardiology, phytotherapy, pharmacy.

SUBSTANCE: invention relates to the field in development of an agent of vegetable origin used for improvement of the functional state and prophylaxis of organic alterations in cardiovascular system, in particular, atherosclerosis. The biologically active supplement used for prophylaxis of cardiovascular diseases, in particular, atherosclerosis comprises clover dry extract, haw-thorn flowers powder, ascorbic and nicotinic acids, and accessory substances taken in the definite ratio. The biologically active supplement is made in the form of tablet or capsule. No adverse responses observed in intake of the supplement. The blood cholesterol level was reduced to the normal value in 68% of patients and reducing morbidity with acute respiratory-viral infections has been noticed. In patients with ischemic heart disease with cholesterolemia the improvement of the state is noted on the background of conventional therapy: the moderate reducing the arterial pressure value in its elevation, improved in the state of health, enhanced working capacity, reduced retrosternal pains, ear noise, vertigo, headache.

EFFECT: valuable medicinal properties of supplement.

1 ex

Up!